Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
Under ICI treatment, HCC patients had a higher risk of hepatitis flare events than non-HCC patients. Abnormal baseline ALT levels are a risk factor for hepatic adverse events. NUC prophylaxis can minimise the risk of HBVr.
Authors
- Muh‐Hwa Yang (ORCID: https://orcid.org/0000-0002-8918-1244)
- Pei‐Chang Lee (ORCID: https://orcid.org/0000-0002-7492-2484)
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- Ming‐Chih Hou (ORCID: https://orcid.org/0000-0002-4886-0718)
- Yi‐Ping Hung (ORCID: https://orcid.org/0000-0001-5221-6813)
- I‐Cheng Lee (ORCID: https://orcid.org/0000-0002-9316-4682)
- Yi‐Hsiang Huang (ORCID: https://orcid.org/0000-0001-5241-5425)
- Chao‐Hua Chiu (ORCID: https://orcid.org/0000-0001-8401-2356)
- Keng‐Hsin Lan (ORCID: https://orcid.org/0000-0003-1781-0838)
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
- Yen‐Hwa Chang
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1111/apt.18403
- Citations
- 12
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.64
Funders
- Taiwan Clinical Oncology Research Foundation
- Taipei Veterans General Hospital
- National Science and Technology Council